In Conversation

Milind Antani – Lead, Pharma, Life Science and Healthcare Practice; Head, Social Sector Practice, Nishith Desai Associates

Milind Antani – Lead, Pharma, Life Science and Healthcare Practice; Head, Social Sector Practice, Nishith Desai Associates

In terms of innovation, the [Indian pharmaceutical] landscape is evolving, but not at a pace that matches global leaders
Luis Abrantes – CEO, Generis

Luis Abrantes – CEO, Generis

We aim to positively surprise our customers and partners with innovative approaches
Agata Jakoncic – Managing Director, MSD Greece, Cyprus & Malta

Agata Jakoncic – Managing Director, MSD Greece, Cyprus & Malta

The way our system has developed means that either we all win together, or we all lose together. Collaboration, therefore, is the key to future success
Albert Wong – CEO, Hong Kong Science and Technology Parks Corporation

Albert Wong – CEO, Hong Kong Science and Technology Parks Corporation

We are open for business and want to bring the best people, best companies, and best investors into Hong Kong
Dalia Samra-Rothe – Delegate, German-Saudi Arabian Liaison Office for Economic Affairs (AHK Saudi Arabia)

Dalia Samra-Rothe – Delegate, German-Saudi Arabian Liaison Office for Economic Affairs (AHK Saudi Arabia)

[Saudi Arabia] is undergoing a truly remarkable transformation, unlike anything seen globally
Sofia Lahlou – Country Manager, Versalya, Morocco

Sofia Lahlou – Country Manager, Versalya, Morocco

[Morocco's] trajectory points towards immense potential and growth
Flavio Devoto – VP Latin America, AbbVie

Flavio Devoto – VP Latin America, AbbVie

Our view is that all stakeholders – not just payers – have responsibility for ensuring access, meaning that building on strong collaborations and public-private partnerships will be crucial
Ahmad Abu Dahab – Vice President Middle East, Turkey, and Northern Africa, SOBI

Ahmad Abu Dahab – Vice President Middle East, Turkey, and Northern Africa, SOBI

We aspire to end the suffering of each patient and work with the healthcare community to ensure that no-one is left behind
See more

In Case You Missed It

InFigures

Belgium, with a total of EUR 5.5 billion in R&D spending in 2021, is the country with the fourth largest research expenditure in the EU and the first per inhabitant.  As a recent study from Deloitte sponsored by the Belgian pharmaceutical industry association, pharma.be, shows, Belgium is also a leader in clinical trials, maintaining its…

The subject of intense industry criticism from the likes of lobby groups, Big Pharma, and biotech alike, the Inflation Reduction Act (IRA) subjects certain drugs to price negotiations directly with industry sponsors in the US for the first time. Ten initial drugs – which accounted for over USD 45 billion in Medicare Part D spending…

We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here